Abstract
As pharmacokinetics in patients undergoing haemodialysis is different from patients with normal renal function, it remains unclear whether chemotherapy can be performed safely for patients with haemodialysis as well as those who have normal renal function. Here, we report a case with recurrence of rectal cancer who received FOLFIRI with bevacizumab chemotherapy under haemodialysis, and obtained good tumor control. A 47-year-old woman had undergone haemodialysis for 10 years due to chronic renal failure. At 45 years of age, she received abdominoperineal resection due to rectal cancer (pStage II). Four months after the surgery, liver metastasis was found, for which partial resection of the liver and adjuvant chemotherapy [UFT (400 mg/body)/UZEL (75 mg/body)] were performed. Eighteen months after the liver resection, multiple lung metastases were found. Therefore, intensive chemotherapy using FOLFIRI (CPT-11: 90 mg/m 2) with bevacizumab (2.5 mg/m 2) was performed. Severe neutropenia (grade 3, 4), but not non-hematologic adverse events such as diarrhea and bevacizumab-specific adverse events, was observed. As she did not recover easily from neutropenia in spite of treatment with G-CSF, a dose reduction of the FOLFIRI regimen was gradually performed. Although chemotherapy was conducted approximately monthly, the tumor response reflected a stable disease 8 months after 8 courses of chemotherapy. We suggest that it is important to investigate the pharmacokinetics of toxic agents such as CPT-11, (SN38) for dose modification, and for the safe and continuous chemotherapy of patients receiving haemodialysis.
| Original language | English |
|---|---|
| Pages (from-to) | 983-986 |
| Number of pages | 4 |
| Journal | Japanese Journal of Cancer and Chemotherapy |
| Volume | 39 |
| Issue number | 6 |
| Publication status | Published - 2012 Jun |
Fingerprint
Keywords
- Bevacizumab
- FOLFIRI
- Haemodialysis
ASJC Scopus subject areas
- Cancer Research
- Oncology
Cite this
FOLFIRI with bevacizumab chemotherapy for a patient with recurrence of rectal cancer under haemodialysis for chronic renal failure. / Hoshino, Hiroki; Ishii, Yoshiyuki; Hasegawa, Hirotoshi; Endo, Takashi; Ochiai, Hiroki; Hoshino, Yoshinori; Matsunaga, Atsushi; Shigeta, Kohei; Seo, Yuki; Hoshino, Go; Kitagawa, Yuukou.
In: Japanese Journal of Cancer and Chemotherapy, Vol. 39, No. 6, 06.2012, p. 983-986.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - FOLFIRI with bevacizumab chemotherapy for a patient with recurrence of rectal cancer under haemodialysis for chronic renal failure
AU - Hoshino, Hiroki
AU - Ishii, Yoshiyuki
AU - Hasegawa, Hirotoshi
AU - Endo, Takashi
AU - Ochiai, Hiroki
AU - Hoshino, Yoshinori
AU - Matsunaga, Atsushi
AU - Shigeta, Kohei
AU - Seo, Yuki
AU - Hoshino, Go
AU - Kitagawa, Yuukou
PY - 2012/6
Y1 - 2012/6
N2 - As pharmacokinetics in patients undergoing haemodialysis is different from patients with normal renal function, it remains unclear whether chemotherapy can be performed safely for patients with haemodialysis as well as those who have normal renal function. Here, we report a case with recurrence of rectal cancer who received FOLFIRI with bevacizumab chemotherapy under haemodialysis, and obtained good tumor control. A 47-year-old woman had undergone haemodialysis for 10 years due to chronic renal failure. At 45 years of age, she received abdominoperineal resection due to rectal cancer (pStage II). Four months after the surgery, liver metastasis was found, for which partial resection of the liver and adjuvant chemotherapy [UFT (400 mg/body)/UZEL (75 mg/body)] were performed. Eighteen months after the liver resection, multiple lung metastases were found. Therefore, intensive chemotherapy using FOLFIRI (CPT-11: 90 mg/m 2) with bevacizumab (2.5 mg/m 2) was performed. Severe neutropenia (grade 3, 4), but not non-hematologic adverse events such as diarrhea and bevacizumab-specific adverse events, was observed. As she did not recover easily from neutropenia in spite of treatment with G-CSF, a dose reduction of the FOLFIRI regimen was gradually performed. Although chemotherapy was conducted approximately monthly, the tumor response reflected a stable disease 8 months after 8 courses of chemotherapy. We suggest that it is important to investigate the pharmacokinetics of toxic agents such as CPT-11, (SN38) for dose modification, and for the safe and continuous chemotherapy of patients receiving haemodialysis.
AB - As pharmacokinetics in patients undergoing haemodialysis is different from patients with normal renal function, it remains unclear whether chemotherapy can be performed safely for patients with haemodialysis as well as those who have normal renal function. Here, we report a case with recurrence of rectal cancer who received FOLFIRI with bevacizumab chemotherapy under haemodialysis, and obtained good tumor control. A 47-year-old woman had undergone haemodialysis for 10 years due to chronic renal failure. At 45 years of age, she received abdominoperineal resection due to rectal cancer (pStage II). Four months after the surgery, liver metastasis was found, for which partial resection of the liver and adjuvant chemotherapy [UFT (400 mg/body)/UZEL (75 mg/body)] were performed. Eighteen months after the liver resection, multiple lung metastases were found. Therefore, intensive chemotherapy using FOLFIRI (CPT-11: 90 mg/m 2) with bevacizumab (2.5 mg/m 2) was performed. Severe neutropenia (grade 3, 4), but not non-hematologic adverse events such as diarrhea and bevacizumab-specific adverse events, was observed. As she did not recover easily from neutropenia in spite of treatment with G-CSF, a dose reduction of the FOLFIRI regimen was gradually performed. Although chemotherapy was conducted approximately monthly, the tumor response reflected a stable disease 8 months after 8 courses of chemotherapy. We suggest that it is important to investigate the pharmacokinetics of toxic agents such as CPT-11, (SN38) for dose modification, and for the safe and continuous chemotherapy of patients receiving haemodialysis.
KW - Bevacizumab
KW - FOLFIRI
KW - Haemodialysis
UR - http://www.scopus.com/inward/record.url?scp=84865497731&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84865497731&partnerID=8YFLogxK
M3 - Article
C2 - 22705698
AN - SCOPUS:84865497731
VL - 39
SP - 983
EP - 986
JO - Japanese Journal of Cancer and Chemotherapy
JF - Japanese Journal of Cancer and Chemotherapy
SN - 0385-0684
IS - 6
ER -